We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.02%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.7B
AUM Growth
-$133M
Cap. Flow
-$379M
Cap. Flow %
-14.04%
Top 10 Hldgs %
54.24%
Holding
107
New
20
Increased
12
Reduced
35
Closed
22

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$157M
2
OMDA
Omada Health Inc
OMDA
+$42M
3
ROIV icon
Roivant Sciences
ROIV
+$36.1M
4
CAI
Caris Life Sciences
CAI
+$29.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.8M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$104M
2
FOLD
Amicus Therapeutics
FOLD
+$90.7M
3
SLNO
Soleno Therapeutics
SLNO
+$80.5M
4
VRNA
Verona Pharma
VRNA
+$78.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$42.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
101
Ocular Therapeutix
OCUL
$2.34B
– –
-915,775
Closed -$6.71M
PCVX icon
102
Vaxcyte
PCVX
$9.1B
– –
-706,567
Closed -$26.7M
RCKT icon
103
Rocket Pharmaceuticals
RCKT
$424M
– –
-140,726
Closed -$939K
TRAW icon
104
Traws Pharma
TRAW
$8.45M
– –
-421,781
Closed -$970K
OKUR
105
OnKure Therapeutics
OKUR
$145M
– –
-1,004,439
Closed -$4.32M
KMTS
106
Kestra Medical Technologies
KMTS
$1.5B
– –
-200,000
Closed -$4.98M
ITCI
107
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-786,358
Closed -$104M
1 2 3 4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Perceptive Advisors held 107 positions worth $2.7B, down 4.7% from $2.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors withdrew a net $379M in Q2 2025, closing 22 positions and reducing 35 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Ascendis Pharma A/S worth $166M.

  • Perceptive Advisors's largest Q2 2025 buy was Ascendis Pharma A/S: 963,886 shares worth $166M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q2 2025, an estimated $17.8M increase.
  • Perceptive Advisors's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $90.7M.
  • Perceptive Advisors fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.7B portfolio in Q2 2025.
  • Perceptive Advisors opened 20 new positions and closed 22 in Q2 2025.
  • Perceptive Advisors's portfolio value fell 4.7% quarter-over-quarter to $2.7B.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.